lobbying_activities: 1953530

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1953530	734c605d-a7a9-4a99-892e-643ba9086316	Q1	APOTEX CORP.	310973	APOTEX CORP.	2017	first_quarter	PHA	Federal policy relating to the reauthorization of the Generic Drug User Fee Act; Federal policy relating to the cost of prescription pharmaceuticals; Federal policy relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; HR 749, the Lower Drug Costs Through Competition Act, provisions relating to priority review vouchers for and expedited approval of certain generic drug applications, and Risk Evaluation and Mitigation (REMS) programs; and Draft legislation (no bill number) related to generic drug exclusivity and the review of Abbreviated New Drug Applications (ANDAs).	HOUSE OF REPRESENTATIVES,SENATE		160000	0	0	2017-04-16T21:04:18.540000-04:00